Effects of NXY-059 in experimental stroke: an individual animal meta-analysisNeuroprotection for stroke: current status and future perspectivesThe exact science of stroke thrombolysis and the quiet art of patient selectionFast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trialTsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagyStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaStroke: working toward a prioritized world agendaGlial and neuronal control of brain blood flowAssessing research impact in academic clinical medicine: a study using Research Excellence Framework pilot impact indicatorsEpendymal ciliary dysfunction and reactive astrocytosis in a reorganized subventricular zone after strokeImproved regional cerebral blood flow is important for the protection seen in a mouse model of late phase ischemic preconditioning.Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.Roles of individual prolyl-4-hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice.The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicityHypothermia rescues hippocampal CA1 neurons and attenuates down-regulation of the AMPA receptor GluR2 subunit after forebrain ischemia.The probability of middle cerebral artery MRA flow signal abnormality with quantified CT ischaemic change: targets for future therapeutic studies.A study of the workload and effectiveness of a comprehensive acute stroke service.Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience.Lost in translation: taking neuroprotection from animal models to clinical trials.Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke.C-EPO: ready for prime-time preconditioning?Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.Insular cortical ischaemia does not independently predict acute hypertension or hyperglycaemia within 3 h of onsetStatins are associated with better outcomes after carotid endarterectomy in symptomatic patients.Strategies for therapy in acute ischemic stroke.Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.Good laboratory practice: preventing introduction of bias at the bench.Reprint: Good laboratory practice: preventing introduction of bias at the bench.Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.Improving accountability through alignment: the role of academic health science centres and networks in England.Therapeutic manipulation of the HIF hydroxylases.A Critical Role for Astrocytes in Hypercapnic Vasodilation in Brain.Ischemic stroke in the elderly: an overview of evidence.Organizational models of emerging academic health science centers in England.Cellular and molecular determinants of stroke-induced changes in subventricular zone cell migrationEndovascular stroke treatment today.Neurological complications of acute ischaemic stroke.Cerebral blood flow alteration in neuroprotection following cerebral ischaemia.Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
P50
Q24654761-D4150079-1E3C-4D0F-BC84-49845F0B56D1Q26853031-408DB273-EAC0-40E4-8837-64F8E53F74CDQ27011873-0EC0A2D8-8F69-44D6-B37C-4AD8E391C772Q28222568-99011DC7-6760-4A70-A3BC-0726FAB4813EQ28286093-D0E13BAF-E97A-4060-B96E-2045EDB78431Q28677503-5E817558-8BC1-4F38-B38F-1554BC3DB9B4Q28677657-90017753-7E1E-4F08-8555-69DC26D146CAQ28742458-2D7FB811-7D40-49E6-A285-B6C6E7BDE616Q29620058-34907074-2A04-4B22-A4E5-CBB31C2F803EQ30394353-21FF2609-B3C4-401D-B491-99DEAEC8B639Q30534310-BFB0759B-E8CB-4EE4-8246-A9381433DE34Q33258922-0D362EA4-1FBB-4CF3-8206-9349AD598674Q33938946-844D63AF-8321-42D6-9D97-62BA992A92D9Q34276898-E2D78FA0-1148-4358-9E19-1F795F872257Q34504984-ED4EB3DA-DD96-4972-9BA4-952EA7C79B8EQ34809036-442966D7-1633-4BB9-ACDA-533BC0685308Q35476867-BA11E189-F48A-4A72-BDAA-DA1D20561BD1Q35487972-9CD93861-6D20-4FD9-B651-94B1F5EB2D31Q35666204-6830B5D6-1B90-43A4-AAEA-33F4492E9664Q35832807-AE316352-93F3-4C0D-8B78-64EC38253866Q35905986-54061B03-E9CC-4A24-AD8A-C14C5BCAB6D8Q36054474-52B49923-9B73-468E-9358-4E101445DB69Q36226503-87808541-D3FB-4574-9439-053588CED38EQ36226590-E7BE0CA1-FAAD-4FD9-B662-6C665BA72669Q36265356-D39FB52B-A7AD-4C9A-B758-B3F08DD5DE01Q36700038-018D63A0-7F78-4477-B047-AC3CE8EB7681Q37139530-E89731D6-0BB1-4CDF-B223-E5C3B6C0969FQ37243686-CFFFB393-5096-4163-964F-DD22262394B7Q37271448-8D8AA2EA-32A6-4659-995A-7C617D6BCB9AQ37298322-ECCB9DE1-C325-49F0-BA13-B376B7914873Q37539649-4BFC810E-A1BB-4971-B029-42AC2FB36C56Q37597176-D63CCCF1-A9CC-42A6-9E34-0551BB381D42Q37705488-5859CBBF-482E-4E9E-9E21-54C9820E49DAQ37724591-E81CB839-F879-406F-BBF6-6BCE504ED87CQ37776620-0B73DE36-F302-448B-8888-49723ADF32F9Q37776731-C7F3A91C-0146-4B0D-B0F7-DFFEC39CCA9BQ37828312-A2BE592A-8E5B-4D75-897B-E2FB242CB72BQ37830146-00E298FA-26B2-4C15-AF2C-986091E36A00Q37895012-6FDFF29B-E2C3-415F-B567-5FBFBC285EE8Q37991061-B74BAF7A-0827-4C67-9CC5-C5BF1983328B
P50
description
British neurologist and researcher in stroke medicine
@en
Brits neuroloog
@nl
neurólogo británico
@es
neurólogu británicu
@ast
طبيب أعصاب من المملكة المتحدة
@ar
name
Alastair Buchan
@ast
Alastair Buchan
@ca
Alastair Buchan
@de
Alastair Buchan
@en
Alastair Buchan
@es
Alastair Buchan
@fr
Alastair Buchan
@hu
Alastair Buchan
@it
Alastair Buchan
@nl
Alastair Buchan
@sl
type
label
Alastair Buchan
@ast
Alastair Buchan
@ca
Alastair Buchan
@de
Alastair Buchan
@en
Alastair Buchan
@es
Alastair Buchan
@fr
Alastair Buchan
@hu
Alastair Buchan
@it
Alastair Buchan
@nl
Alastair Buchan
@sl
prefLabel
Alastair Buchan
@ast
Alastair Buchan
@ca
Alastair Buchan
@de
Alastair Buchan
@en
Alastair Buchan
@es
Alastair Buchan
@fr
Alastair Buchan
@hu
Alastair Buchan
@it
Alastair Buchan
@nl
Alastair Buchan
@sl
P69
P214
P244
P1053
B-9095-2009
P106
P1695
P21
P213
0000 0000 4478 2690
P214
P244
no2004032813
P31
P3829
P496
0000-0002-2918-5200
P569
1955-10-16T00:00:00Z
P734
P735
P7859
lccn-no2004032813